Recent Publications from BioSynthema and Collaborators

Janssen PJ, de Visser M, Verwijnen SM, Bernard BF, Srinivasan A, Erion JL, Breeman WA, Vulto AG, Krenning EP, de Jong M.  Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors. Cancer Biother Radiopharm. 2007;22:374-81.

Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS.  Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Bioconjug Chem. 2007;18:724-30.

de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M. Novel (111)In-labelled bombesin analogues for molecular imaging of prostate tumours.  Eur J Nucl Med Mol Imaging. 2007;34:1228-38.

Poria RB, Norenberg JP, Anderson TL, Erion J, Wagner CR, Arterburn JB, Larson RS.  Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia. Cancer Biother Radiopharm. 2006;21:418-26.

Capello A, Krenning EP, Bernard BF, Breeman WA, Erion JL, de Jong M.  Anticancer activity of targeted proapoptotic peptides.  J Nucl Med. 2006;47:122-9.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M.  Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm. 2004;19:173-80.

Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL.  Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem. 2003;46:3403-11.

de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, de Jong M.  Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.  Eur J Nucl Med Mol Imaging. 2003;30:1134-9.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP.  Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.  Eur J Nucl Med Mol Imaging. 2003;30:917-20.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-22.

Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M.  The addition of DTPA to [177Lu DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.  Eur J Nucl Med Mol Imaging. 2003;30:312-5.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.  Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.  J Nucl Med. 2002 Dec;43(12):1650-6.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ.  DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.  Bioconjug Chem. 2002;13:721-8.

Achilefu S, Jimenez HN, Dorshow RB, Bugaj JE, Webb EG, Wilhelm RR, Rajagopalan R, Johler J, Erion JL.  Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.  J Med Chem. 2002;45:2003-15.

Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.  Int J Cancer. 2001;94:873-7.

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.  Eur J Nucl Med. 2001;28:1319-25.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.  [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

Int J Cancer. 2001 Jun 1;92(5):628-33. Bugaj JE, Erion JL, Johnson MA, Schmidt MA, Srinivasan A.  Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats. Nucl Med Biol. 2001;28:327-34.